Even after out-licensing a pair of hepatitis C therapeutic candidates to Vertex, which was bidding on finding a contender as a new wave of transformational drugs approached the market, South San Francisco-based Alios BioPharma stubbornly maintained a very low profile.
Vertex is jettisoning one as a dud while racing ahead with the second into a mid-stage study slated to begin in a matter of weeks.
A little more than a year after Vertex licensed in a pair of "nucs" from Alios BioPharma in a high-stakes bid to develop an oral, interferon-free approach to hepatitis C, Vertex is jettisoning one as a dud while racing ahead with the second into a mid-stage study slated to begin in a matter of weeks.
Vertex investors barely noted yesterday evening that revenue from Incivek slipped in the second quarter. Their attention was on ALS-2200, a hepatitis C nucleotide analogue that has elbowed its way into the frenzied race for a near-term approval for an all-oral therapeutic regimen.
Vertex ($VRTX) today unveiled a slate of somewhat positive interim midstage results for an all-oral combo regimen that includes its game-changing drug Incivek.
Alios BioPharma has taken its attack on infectious bugs to China, where the South San Francisco-based biotech has struck a deal with the University of Hong Kong's tech transfer outfit Versitech,
Now that Vertex's ($VRTX) lead blockbuster program for Incivek has crossed the finish line at the FDA, the biotech company is committing up to $775 million--$60 million upfront--to land global rights
With the help of new investor SR One, the corporate venture fund of GlaxoSmithKline, Alios BioPharma has raised an additional $8 million to advance its preclinical programs toward proof-of-concept.
The South San Francisco start-up Alios BioPharma has rounded up commitments on $24 million in venture capital and plans to use the funds to start advancing its preclinical programs toward